Some of pharma’s biggest bets met very different fates at the FDA this week.
Summit Therapeutics disclosed an FDA rejection of its closely watched lung cancer drug ivonescimab for a form of the disease on Sunday. On Monday, Roche secured FDA approval for its breast cancer drug Wilserdly, which was followed a day later by an accelerated approval for GSK’s lung cancer drug Nelkarmi.
But for drugmakers more broadly, winning FDA approval is just the first hurdle. Once a drug hits the market, another question looms: How much of that market can it actually capture?
In an October analysis of the 20 highest-grossing drug launches (excluding vaccines) by inflation-adjusted worldwide sales in their first year on the market, pharma positioning expert Mike Rea found that 13 were treatments for either COVID-19 or hepatitis C.
These products had a common advantage: Substantial demand already existed before they hit the market. And as the initial rush subsided, so did sales for some.
Some drugs launch into a market that’s been waiting for them. Others have to build one or wrest patients away from competitors.
Here are three launches this year that could offer a glimpse of how those strategies will play out in 2027.
Revolution Medicines’ Rasonque: The rush to meet pent-up demand
Few biotechs get the kind of commercial reception Revolution Medicines has enjoyed with its first marketed drug. The FDA approved the RAS-targeting pill Rasonque in August for adults with metastatic pancreatic adenocarcinoma who’ve already received systemic therapy or aren’t candidates for multiagent systemic therapy.
In roughly five weeks on the U.S. market, the drug generated $197.6 million in net product revenue, with more than 5,000 patients receiving the commercial drug by the end of September, according to the company.
The debut speaks to a major unmet need in a notoriously difficult-to-treat disease. In a pivotal trial involving previously treated patients, median overall survival was 13.2 months with Rasonque compared to 6.7 months with standard chemotherapy.
But those early numbers could obscure what demand for the drug looks like down the road. Some patients transitioned from expanded access, others had been awaiting an approved treatment while initial inventory stocking also contributed to revenue. Revolution cautioned against extrapolating the early results to longer-term sales.
Now the biotech is taking that launch international. The European Commission approved Rasonque on Monday for previously treated patients, and access will depend on pricing and reimbursement processes in individual countries.
The challenge in 2027 will be sustaining uptake after the initial U.S. backlog clears while building out the European launch. Meanwhile, trials in earlier treatment settings could further expand the market for Revolution.
J&J’s Icotyde: Growing the pie
Johnson & Johnson’s oral psoriasis drug Icotyde, developed with Protagonist Therapeutics, is taking a different tack.
Approved in March for moderate to severe plaque psoriasis, the first-of-its-kind oral peptide blocks the IL-23 receptor, targeting a pathway already addressed by injectable biologics such as J&J’s Tremfya.
J&J didn’t break out Icotyde sales in its third-quarter results, but the company said on its October earnings call that more than 20,000 U.S. patients had begun treatment. Perhaps the more telling number is that about 60% of patients hadn’t previously received systemic therapy.
As Rea noted in a recent analysis of the launch, that early prescribing pattern offers a clue to the strategic choice J&J made during development. A pill targeting a pathway familiar to dermatologists could draw patients who haven’t ventured beyond topical treatment or other nonsystemic approaches. The opportunity for J&J, then, isn’t just a bigger slice of the systemic treatment market.
It’s a bigger market.
Fresh phase 3 results announced Nov. 6 showed Icotyde was noninferior to injectable ustekinumab (sold as Stelara) on key secondary measures of skin clearance. A day later, J&J reported that its pill met the primary endpoint in a phase 3 study in psoriatic arthritis, a potential new indication. With studies also underway in ulcerative colitis and Crohn’s disease, the psoriasis launch could be a bellwether for a broader immunology franchise.
Vera’s Trutakna: A smaller launch with a big test ahead
In a market where new treatments have proliferated in just a few years, Vera Therapeutics is looking to establish a foothold with its first commercial drug, Trutakna (atacicept-vymj). The FDA granted Trutakna accelerated approval in July to reduce proteinuria, or excess protein in the urine, in adults with primary IgA nephropathy at risk of disease progression.
The biotech reported $10.3 million in third-quarter net product revenue and about 700 patient start forms by Nov. 5. About half of that revenue came from inventory stocking, Vera Chief Commercial Officer Matt Skelton said on the company’s Nov. 5 earnings call, but nearly all the start forms came from patients already receiving treatment for the disease. Skelton pointed to feedback from more than 29,000 sales calls suggesting patients valued at-home administration and highlighted efforts to broaden payer coverage.
And the clinical case is evolving. In a Vera-funded trial published in The New England Journal of Medicine in October, a composite measure of kidney disease progression occurred in 5.1% of patients receiving atacicept and 17.8% of those receiving placebo. Vera submitted for full FDA approval on Nov. 3 and expects a decision in mid-2027.
Still, Vera is entering a competitive market that includes Otsuka’s Voyxact. And a drug targeting the same two immune signaling proteins as Trutakna could soon be on the way: Vertex Pharmaceutical’s povetacicept has an FDA target action date of Nov. 30 for potential accelerated approval.
Vertex is developing the treatment as an at-home injection given every four weeks, in contrast to Trutakna’s weekly dosing. But Vera is also exploring monthly dosing of atacicept and expects to review initial data by year’s end — a potential way to blunt a dosing-frequency advantage for Vertex.
The competition extends beyond IgA nephropathy. On Friday, Roche’s Gazyva became the first FDA-approved treatment specifically for primary membranous nephropathy, a separate kidney disease in which Vera is also studying atacicept. Vera has already shown it can bring a drug to market. In 2027, it could find out how much of that market it can call its own.